Skip to content
The Nexus
DossierENTITY

Vaccines and Related Biological Products Advisory Committee

Coverage of Vaccines and Related Biological Products Advisory Committee in the Nexus archive.

Earliest in view: May 26 · 20:22 UTCMost recent: Jun 18 · 20:26 UTC
Co-mentioned in this coverage
Modernaorganization1FDAorganization1mRNA flu vaccinetopic1Wellington Sunperson1Food and Drug Administrationorganization1XFG subvarianttopic1COVID-19 vaccinetopic12026-2027 respiratory viral seasontopic1
Recent coverage
  • HEALTHJun 18 · 20:26 UTCSTAT NEWS
    STAT+: FDA advisory panel endorses Moderna mRNA flu vaccine that was subject of controversy

    An FDA advisory panel unanimously endorsed Moderna's mRNA flu vaccine, concluding its benefits outweigh risks for adults aged 50-64 and those 65+. The FDA may license it via traditional and accelerated pathways, with existing vaccines having used similar routes. Wellington Sun, a former FDA employee who later worked for Moderna, commented on accelerated pathways during the meeting.

  • HEALTHMay 26 · 20:22 UTCTHE HILL
    FDA advisers to weigh updated COVID vaccine targeting XFG subvariant

    The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) will meet to discuss updating the COVID-19 vaccine to target the XFG subvariant for the 2026-2027 respiratory season. The meeting aims to determine whether current vaccines should be modified to address this emerging variant.